diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM9378diaendo-9378Research ArticleОбзорыReviewПатогенетические аспекты нарушения метаболизма гепсидина и феррокинетики при патологии углеводного обменаPathogenetic aspects of hepcidin metabolism and ferrocinetics dysregulation in carbohydrate metabolism disordershttps://orcid.org/0000-0001-9011-8720СапринаТатьяна ВладимировнаSaprinaTatiana V.

д.м.н., профессор

MD, PhD, Professor

tanja.v.saprina@mail.ruhttps://orcid.org/0000-0002-9034-7264ЗимаАнастасия ПавловнаZimaAnastasia P.

д.м.н., профессор

MD, PhD, Professor

zima2302@gmail.comhttps://orcid.org/0000-0001-7148-6739МусинаНадежда НурлановнаMusinaNadezhda N.

аспирант

MD, PhD student

nadiezhda-musina@mail.ruhttps://orcid.org/0000-0002-8016-4755ПрохоренкоТатьяна СергеевнаProkhorenkoTatiana S.

к.м.н., н.с.

MD, PhD, research associate

mmikld.ssmu@gmail.comhttps://orcid.org/0000-0003-0676-3968ЛатыповаАлина ВикторовнаLatypovaAlina V.

аспирант

MD, PhD student

lina.lae@gmail.comhttps://orcid.org/0000-0002-2669-8393ШахмановаНаталья СергеевнаShakhmanovaNatalia S.

аспирант

MD, PhD student

shakhmanovanatasha@gmail.comhttps://orcid.org/0000-0003-2460-467XБудееваСветлана ВасильевнаBudeevaSvetlana V.

соискатель кафедры патофизиологии

MD, postgraduate student

budeeva.svetlana@yandex.ru<p>Сибирский государственный медицинский университет</p>Россия<p>Siberian State Medical University</p>Russian Federation201818022019216506512Copyright &#x00A9; Саприна Т.В., Зима А.П., Мусина Н.Н., Прохоренко Т.С., Латыпова А.В., Шахманова Н.С., Будеева С.В., 20182018Саприна Т.В., Зима А.П., Мусина Н.Н., Прохоренко Т.С., Латыпова А.В., Шахманова Н.С., Будеева С.В.Saprina T.V., Zima A.P., Musina N.N., Prokhorenko T.S., Latypova A.V., Shakhmanova N.S., Budeeva S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/9378

На сегодняшний день идет накопление данных относительно роли гепсидина – гормона, регулирующего метаболизм железа, в патогенезе нарушений углеводного обмена. Нарушение продукции гепсидина у пациентов с сахарным диабетом (СД) может носить двунаправленный характер и проявляться как снижением его продукции и сопровождаться синдромом перегрузки железом, так и повышением синтеза и приводить к развитию анемии хронических заболеваний. Установлено, что анемический синдром оказывает влияние на концентрацию гликированного гемоглобина, независимо от состояния углеводного обмена. Тем не менее не проводилось комплексного анализа механизмов дизрегуляции гепсидина и оценки взаимоотягощающего влияния нарушений феррокинетики и патологии углеводного обмена. Активно обсуждается вопрос ассоциации СД с развитием нейродегенеративных заболеваний, а также роль железа в патогенезе болезней Альцгеймера и Паркинсона. В данной статье приведен обзор данных зарубежной литературы касательно механизмов регуляции продукции гепсидина и нарушения обмена данного пептида при различных нозологиях, в том числе СД и нейродегенеративных заболеваниях. Представлены результаты исследований, направленных на поиск методов терапевтической коррекции нарушений феррокинетики, ассоциированных с дизрегуляцией гепсидина.

Hepcidin, a hormone regulating iron metabolism, has received attention for its role in the pathogenesis of dysregulations in carbohydrate metabolism. Hepcidin disorders in patients with diabetes mellitus are bi-directional: manifesting as iron overload syndrome in cases of decreased hepcidin production and as anaemia of chronic disease in cases of hepcidin hypersecretion. However, till date, detailed analyses of mechanisms underlying hepcidin dysregulation have not been conducted nor have the interactions of ferrocinetic and carbohydrate-metabolic disorders been examined. An association between diabetes mellitus and neurodegenerative diseases as well as the role of iron metabolism in Alzheimer or Parkinson diseases is a subject of ongoing research. This review provides a summary of the current understanding of hepcidin regulation and its disorders in various diseases, including diabetes mellitus and neurodegenerative diseases. In addition, we provide an overview of the available therapies that address ferrocinetic disorders resulting from the dysregulation of hepcidin.

сахарный диабетгепсидинанемия хронических заболеванийсиндром перегрузки железомболезнь Альц геймераболезнь Паркинсонаdiabetes mellitushepcidinanemia of chronic diseaseiron overloadAlzheimer diseaseParkinson diseaseПоисково-аналитическая работа по подготовке рукописи проведена при финансовой поддержке гранта РФФИ р_а № 16-44-700246.The research is financed with grant Russian Fund of Fundamental Investigations (RFFI) р_а № 16-44-700246.ReferencesKrause A, Neitz S, Mägert H-J, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480(2-3):147-150. doi: 10.1016/s0014-5793(00)01920-7Krause A, Neitz S, Mägert H-J, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480(2-3):147-150. doi: 10.1016/s0014-5793(00)01920-7Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. J Biol Chem. 2001;276(11):7806-7810. doi: 10.1074/jbc.M008922200Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. J Biol Chem. 2001;276(11):7806-7810. doi: 10.1074/jbc.M008922200Sow FB, Florence WC, Satoskar AR, et al. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol. 2007;82(4):934-945. doi: 10.1189/jlb.0407216Sow FB, Florence WC, Satoskar AR, et al. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol. 2007;82(4):934-945. doi: 10.1189/jlb.0407216Kulaksiz H, Fein E, Redecker P, et al. Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol. 2008;197(2):241-249. doi: 10.1677/JOE-07-0528Kulaksiz H, Fein E, Redecker P, et al. Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol. 2008;197(2):241-249. doi: 10.1677/JOE-07-0528Addo L, Ikuta K, Tanaka H, et al. The three isoforms of hepcidin in human serum and their processing determined by liquid chromatography-tandem mass spectrometry (LC-tandem MS). Int J Hematol. 2016;103(1):34-43. doi: 10.1007/s12185-015-1885-yAddo L, Ikuta K, Tanaka H, et al. The three isoforms of hepcidin in human serum and their processing determined by liquid chromatography-tandem mass spectrometry (LC-tandem MS). Int J Hematol. 2016;103(1):34-43. doi: 10.1007/s12185-015-1885-yDe Domenico I, Zhang TY, Koening CL, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010;120(7):2395-2405. doi: 10.1172/JCI42011De Domenico I, Zhang TY, Koening CL, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010;120(7):2395-2405. doi: 10.1172/JCI42011Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41-53. doi: 10.1016/j.blre.2012.12.003Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41-53. doi: 10.1016/j.blre.2012.12.003Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99(7):4596-4601. doi: 10.1073/pnas.072632499Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99(7):4596-4601. doi: 10.1073/pnas.072632499Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112(4):1503-1509. doi: 10.1182/blood-2008-03-143354Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112(4):1503-1509. doi: 10.1182/blood-2008-03-143354D'Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012;57(5):1052-1060. doi: 10.1016/j.jhep.2012.06.015D'Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012;57(5):1052-1060. doi: 10.1016/j.jhep.2012.06.015Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008;8(6):502-511. doi: 10.1016/j.cmet.2008.09.012Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008;8(6):502-511. doi: 10.1016/j.cmet.2008.09.012Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088-1092. doi: 10.1126/science.1157121Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088-1092. doi: 10.1126/science.1157121Lee DH, Zhou LJ, Zhou Z, et al. Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis. Blood. 2010;115(15):3136-3145. doi: 10.1182/blood-2009-11-251199Lee DH, Zhou LJ, Zhou Z, et al. Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis. Blood. 2010;115(15):3136-3145. doi: 10.1182/blood-2009-11-251199Enns CA, Ahmed R, Zhang AS. Neogenin interacts with matriptase-2 to facilitate hemojuvelin cleavage. J Biol Chem. 2012;287(42):35104-35117. doi: 10.1074/jbc.M112.363937Enns CA, Ahmed R, Zhang AS. Neogenin interacts with matriptase-2 to facilitate hemojuvelin cleavage. J Biol Chem. 2012;287(42):35104-35117. doi: 10.1074/jbc.M112.363937Armitage AE, Eddowes LA, Gileadi U, et al. Hepcidin regulation by innate immune and infectious stimuli. Blood. 2011;118(15):4129-4139. doi: 10.1182/blood-2011-04-351957Armitage AE, Eddowes LA, Gileadi U, et al. Hepcidin regulation by innate immune and infectious stimuli. Blood. 2011;118(15):4129-4139. doi: 10.1182/blood-2011-04-351957Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433. doi: 10.1182/blood-2011-01-258467Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433. doi: 10.1182/blood-2011-01-258467Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276. doi: 10.1172/JCI20945Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276. doi: 10.1172/JCI20945Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684. doi: 10.1038/ng.2996Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684. doi: 10.1038/ng.2996Perlstein TS, Pande R, Berliner N, Vanasse GJ. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011;117(10):2800-2806. doi: 10.1182/blood-2010-09-309708Perlstein TS, Pande R, Berliner N, Vanasse GJ. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011;117(10):2800-2806. doi: 10.1182/blood-2010-09-309708Kumar VA, Kujubu DA, Sim JJ, et al. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol. 2011;24(1):98-105. doi: 10.5301/jn.2010.1830Kumar VA, Kujubu DA, Sim JJ, et al. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol. 2011;24(1):98-105. doi: 10.5301/jn.2010.1830Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25(3):564-572. doi: 10.1681/ASN.2013040355Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25(3):564-572. doi: 10.1681/ASN.2013040355Zughaier SM, Alvarez JA, Sloan JH, et al. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014;1(1):19-25. doi: 10.1016/j.jcte.2014.01.003Zughaier SM, Alvarez JA, Sloan JH, et al. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014;1(1):19-25. doi: 10.1016/j.jcte.2014.01.003Pantopoulos K. Function of the hemochromatosis protein HFE: lessons from animal models. World J Gastroenterol. 2008;14(45):6893-6901. doi: 10.3748/wjg.14.6893Pantopoulos K. Function of the hemochromatosis protein HFE: lessons from animal models. World J Gastroenterol. 2008;14(45):6893-6901. doi: 10.3748/wjg.14.6893Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005;128(2):470-479. doi: 10.1053/j.gastro.2004.11.057Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005;128(2):470-479. doi: 10.1053/j.gastro.2004.11.057Speletas M, Kioumi A, Loules G, et al. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV. Blood Cells Mol Dis. 2008;40(3):353-359. doi: 10.1016/j.bcmd.2007.09.011Speletas M, Kioumi A, Loules G, et al. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV. Blood Cells Mol Dis. 2008;40(3):353-359. doi: 10.1016/j.bcmd.2007.09.011Altes A, Bach V, Ruiz A, et al. Mutations in HAMP and HJV genes and their impact on expression of clinical hemochromatosis in a cohort of 100 Spanish patients homozygous for the C282Y mutation of HFE gene. Ann Hematol. 2009;88(10):951-955. doi: 10.1007/s00277-009-0705-yAltes A, Bach V, Ruiz A, et al. Mutations in HAMP and HJV genes and their impact on expression of clinical hemochromatosis in a cohort of 100 Spanish patients homozygous for the C282Y mutation of HFE gene. Ann Hematol. 2009;88(10):951-955. doi: 10.1007/s00277-009-0705-yEuropean Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22. doi: 10.1016/j.jhep.2010.03.001European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22. doi: 10.1016/j.jhep.2010.03.001Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40(5):569-571. doi: 10.1038/ng.130Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40(5):569-571. doi: 10.1038/ng.130Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis. 2011;43:89–95. doi: 10.1016/j.dld.2010.07.006Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis. 2011;43:89–95. doi: 10.1016/j.dld.2010.07.006Milic S, Mikolasevic I, Orlic Let al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144-2151. doi: 10.12659/MSM.896494Milic S, Mikolasevic I, Orlic Let al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144-2151. doi: 10.12659/MSM.896494Taes YE, Wuyts B, Boelaert JR, et al. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med. 2004;42(4):387-389. doi: 10.1515/CCLM.2004.069Taes YE, Wuyts B, Boelaert JR, et al. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med. 2004;42(4):387-389. doi: 10.1515/CCLM.2004.069Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther Apher Dial. 2013;17(1):1-8. doi: 10.1111/1744-9987.12001Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther Apher Dial. 2013;17(1):1-8. doi: 10.1111/1744-9987.12001Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(9):1681-1689. doi: 10.2215/CJN.05990809Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(9):1681-1689. doi: 10.2215/CJN.05990809Uehata T, Tomosugi N, Shoji T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant. 2012;27(3):1076-1083. doi: 10.1093/ndt/gfr431Uehata T, Tomosugi N, Shoji T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant. 2012;27(3):1076-1083. doi: 10.1093/ndt/gfr431Barsan L, Stanciu A, Stancu S, et al. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology. 2015;20(9):543-552. doi: 10.1179/1607845415Y.0000000004Barsan L, Stanciu A, Stancu S, et al. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology. 2015;20(9):543-552. doi: 10.1179/1607845415Y.0000000004Aregbesola A, Voutilainen S, Virtanen JK, et al. Serum hepcidin concentrations and type 2 diabetes. World J Diabetes. 2015;6(7):978-982. doi: 10.4239/wjd.v6.i7.978Aregbesola A, Voutilainen S, Virtanen JK, et al. Serum hepcidin concentrations and type 2 diabetes. World J Diabetes. 2015;6(7):978-982. doi: 10.4239/wjd.v6.i7.978Sam AH, Busbridge M, Amin A, et al. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med. 2013;30(12):1495-1499. doi: 10.1111/dme.12262Sam AH, Busbridge M, Amin A, et al. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med. 2013;30(12):1495-1499. doi: 10.1111/dme.12262Jiang F, Sun ZZ, Tang YT, et al. Hepcidin expression and iron parameters change in Type 2 diabetic patients. Diabetes Res Clin Pract. 2011;93(1):43-48. doi: 10.1016/j.diabres.2011.03.028Jiang F, Sun ZZ, Tang YT, et al. Hepcidin expression and iron parameters change in Type 2 diabetic patients. Diabetes Res Clin Pract. 2011;93(1):43-48. doi: 10.1016/j.diabres.2011.03.028Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329-341. doi: 10.1016/j.cmet.2013.02.007Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329-341. doi: 10.1016/j.cmet.2013.02.007Rajpathak SN, Crandall JP, Wylie-Rosett J, et al. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta. 2009;1790(7):671-681. doi: 10.1016/j.bbagen.2008.04.005Rajpathak SN, Crandall JP, Wylie-Rosett J, et al. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta. 2009;1790(7):671-681. doi: 10.1016/j.bbagen.2008.04.005Equitani F, Fernandez-Real JM, Menichella G, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care. 2008;31(1):3-8. doi: 10.2337/dc07-0939Equitani F, Fernandez-Real JM, Menichella G, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care. 2008;31(1):3-8. doi: 10.2337/dc07-0939Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care. 2007;30(9):2309-2313. doi: 10.2337/dc07-0642Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care. 2007;30(9):2309-2313. doi: 10.2337/dc07-0642Pechlaner R, Weiss G, Bansal S, et al. Inadequate hepcidin serum concentrations predict incident type 2 diabetes mellitus. Diabetes Metab Res Rev. 2016;32(2):187-192. doi: 10.1002/dmrr.2711Pechlaner R, Weiss G, Bansal S, et al. Inadequate hepcidin serum concentrations predict incident type 2 diabetes mellitus. Diabetes Metab Res Rev. 2016;32(2):187-192. doi: 10.1002/dmrr.2711Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol. 2013;182(6):2254-2263. doi: 10.1016/j.ajpath.2013.02.019Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol. 2013;182(6):2254-2263. doi: 10.1016/j.ajpath.2013.02.019McCranor BJ, Langdon JM, Prince OD, et al. Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age. Haematologica. 2013;98(10):1633-1640. doi: 10.3324/haematol.2013.087114McCranor BJ, Langdon JM, Prince OD, et al. Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age. Haematologica. 2013;98(10):1633-1640. doi: 10.3324/haematol.2013.087114Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443. doi: 10.1016/j.bbamcr.2012.01.014Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443. doi: 10.1016/j.bbamcr.2012.01.014Rametta R, Dongiovanni P, Pelusi S, et al. Hepcidin resistance in dysmetabolic iron overload. Liver Int. 2016;36(10):1540-1548. doi: 10.1111/liv.13124Rametta R, Dongiovanni P, Pelusi S, et al. Hepcidin resistance in dysmetabolic iron overload. Liver Int. 2016;36(10):1540-1548. doi: 10.1111/liv.13124Christy AL, Manjrekar PA, Babu RP, et al. Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. Iran Biomed J. 2014;18(2):88-93. doi: 10.6091/ibj.1257.2014Christy AL, Manjrekar PA, Babu RP, et al. Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. Iran Biomed J. 2014;18(2):88-93. doi: 10.6091/ibj.1257.2014Sluiter WJ, Van Essen LH, Reitsma WD, Doorenbos H. Glycosylated HÆmoglobin and Iron Deficiency. Lancet. 1980;316(8193):531-532. doi: 10.1016/s0140-6736(80)91853-xSluiter WJ, Van Essen LH, Reitsma WD, Doorenbos H. Glycosylated HÆmoglobin and Iron Deficiency. Lancet. 1980;316(8193):531-532. doi: 10.1016/s0140-6736(80)91853-xHashimoto K, Noguchi S, Morimoto Y, et al. A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care. 2008;31(10):1945-1948. doi: 10.2337/dc08-0352Hashimoto K, Noguchi S, Morimoto Y, et al. A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care. 2008;31(10):1945-1948. doi: 10.2337/dc08-0352Crichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm (Vienna). 2011;118(3):301-314. doi: 10.1007/s00702-010-0470-zCrichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm (Vienna). 2011;118(3):301-314. doi: 10.1007/s00702-010-0470-zRaha AA, Vaishnav RA, Friedland RP, et al. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathol Commun. 2013;1:55. doi: 10.1186/2051-5960-1-55Raha AA, Vaishnav RA, Friedland RP, et al. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathol Commun. 2013;1:55. doi: 10.1186/2051-5960-1-55Du F, Qian ZM, Luo Q, et al. Hepcidin Suppresses Brain Iron Accumulation by Downregulating Iron Transport Proteins in Iron-Overloaded Rats. Mol Neurobiol. 2015;52(1):101-114. doi: 10.1007/s12035-014-8847-xDu F, Qian ZM, Luo Q, et al. Hepcidin Suppresses Brain Iron Accumulation by Downregulating Iron Transport Proteins in Iron-Overloaded Rats. Mol Neurobiol. 2015;52(1):101-114. doi: 10.1007/s12035-014-8847-xKurian MA, McNeill A, Lin JP, Maher ER. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol. 2011;53(5):394-404. doi: 10.1111/j.1469-8749.2011.03955.xKurian MA, McNeill A, Lin JP, Maher ER. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol. 2011;53(5):394-404. doi: 10.1111/j.1469-8749.2011.03955.xPyatigorskaya N, Sharman M, Corvol JC, et al. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry. Mov Disord. 2015;30(8):1077-1084. doi: 10.1002/mds.26218Pyatigorskaya N, Sharman M, Corvol JC, et al. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry. Mov Disord. 2015;30(8):1077-1084. doi: 10.1002/mds.26218Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001;276(47):44284-44296. doi: 10.1074/jbc.M105343200Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001;276(47):44284-44296. doi: 10.1074/jbc.M105343200Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012;120(18):3829-3836. doi: 10.1182/blood-2012-07-440743Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012;120(18):3829-3836. doi: 10.1182/blood-2012-07-440743Schmidt PJ, Racie T, Westerman M, et al. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-thalassemia intermedia. Am J Hematol. 2015;90(4):310-313. doi: 10.1002/ajh.23934Schmidt PJ, Racie T, Westerman M, et al. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-thalassemia intermedia. Am J Hematol. 2015;90(4):310-313. doi: 10.1002/ajh.23934Hashizume M, Uchiyama Y, Horai N, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2010;30(7):917-923. doi: 10.1007/s00296-009-1075-4Hashizume M, Uchiyama Y, Horai N, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2010;30(7):917-923. doi: 10.1007/s00296-009-1075-4Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013;121(12):2311-2315. doi: 10.1182/blood-2012-09-456756Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013;121(12):2311-2315. doi: 10.1182/blood-2012-09-456756

The authors declare that there are no conflicts of interest present.